Abbott Laboratories dropped from Russell Top 50, shares hold above Tradegate level

Abbott Laboratories faces a quiet index change as the stock is removed from the Russell Top 50 Index, while the shares continue to trade in a narrow range on Tradegate and remain a core S&P 500 healthcare name.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-29, 14:05.

Abbott Laboratories (US0028241000) has been removed from the Russell Top 50 Index in the latest June reconstitution, according to index provider disclosures cited by MarketScreener. The shares remain part of the S&P 500 and continue to trade on Tradegate in euros alongside their primary NYSE listing.

What Russell changed this week

The Russell index family conducts its annual reconstitution each June, adjusting membership based on updated market capitalizations and other criteria, and Abbott Laboratories was dropped from the Russell Top 50 Index in the 26 June update. The adjustment reflects shifting size rankings in the US large-cap universe, where other healthcare and technology names now occupy the top slots.

Despite the change in this specific index, Abbott Laboratories continues to be followed as a major US healthcare stock, with multiple analyst houses covering the company and its diagnostics and medical devices portfolio. Index changes of this type can trigger mechanical flows from passive funds tracking the affected benchmarks but do not alter the underlying business fundamentals.

Position among healthcare peers

Abbott Laboratories competes with other diversified health-care companies such as Johnson & Johnson and Medtronic in areas ranging from cardiovascular devices to diagnostics. The stock remains part of the broader S&P 500 healthcare sector basket, which includes large peers across pharmaceuticals, biotechnology and medical technology.

Analysts often compare Abbott’s growth and margin profile with these peers, using consensus estimates aggregated by platforms such as MarketScreener to track expected earnings and revenue trends. Recent coverage has highlighted Abbott’s exposure to diabetes care through its FreeStyle Libre sensor platform and its broader diagnostics franchises.

The business behind the stock

Abbott Laboratories generates revenue primarily from medical devices, diagnostics, nutritional products and branded generic pharmaceuticals, with the last full-year data showing a diversified four-pillar structure. A key growth driver has been the FreeStyle Libre continuous glucose monitoring system, which has gained broad uptake among people with diabetes and is regularly expanded with new sensor iterations and software features.

Where the shares trade today

Abbott Laboratories shares (US0028241000) trade on 2026-06-29 at 83.22 euros on Tradegate, with an intraday high of 83.54 euros and a low of 82.76 euros, and a reported last-change of around 0.97 percent for the session.

Abbott Laboratories in brief

• Company: Abbott Laboratories
• ISIN: US0028241000
• WKN: 850103
• Ticker: ABT
• Trading venue: Tradegate, NYSE
• Price (as of 2026-06-29, 14:05): 83.22 euros
• Market cap: approximately 150 billion US dollars (as of 2026-06-29)
• Sector / industry: Healthcare, medical devices & diagnostics
• Index membership: S&P 500, various sector indices
• Next earnings date: 2026-07-25 (company earnings call schedule)

This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources deemed reliable but without any guarantee; investors should conduct their own research or consult a qualified advisor before making investment decisions.